<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidemiological studies suggest a positive association between <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2D) with the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo>, <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, increased levels of IGF, elevated levels of steroid and <z:chebi fb="0" ids="25905">peptide hormones</z:chebi>, and inflammatory markers appear to play a role in the connection between these different diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Medications, such as <z:chebi fb="0" ids="6801">metformin</z:chebi> and exogenous insulin, used to treat T2D may affect the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality </plain></SENT>
<SENT sid="3" pm="."><plain>Newer therapies targeting the insulin and IGF1 systems are being developed for use in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
</text></document>